Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.
Epistemonikos ID: 8414d95d8806b5747a7a1ef50ee5f21de7aa6d85
First added on: May 11, 2024